Peter de Keizer
Associate Professor at UMC Utrecht, Founder and Managing Director at Cleara Biotech
Peter de Keizer is the founder and managing director of Cleara Biotech B.V. He has 10+ years experience in valorization, intellectual property and preclinical research and development. He is and associate professor “Senescence in Cancer and Aging” at the University Medical Center Utrecht, the Netherlands. Peter was trained as a molecular biologist at Utrecht University and Harvard Medical School / Mass General Hospital, Boston, MA, USA (2004). He performed is PhD in 2009 in the field of FOXO signaling, knowledge he employed during his postdoctoral work at the Buck Institute for Research on Aging in Novato, CA, USA (2012) to develop the first compounds to eliminate senescent cells: FOXO4-based peptides. In 2017, he showed the translational power eliminating at least some types of senescent cells in mice, which resulted in a restoration of tissue homeostasis in models for aging and chemotoxicity (Cell, 2017; cited >700 times). In 2018, he joined the UMC Utrecht, the Netherlands, to investigate subtypes of senescence, where he became associate professor in 2020.
Visit website: https://www.clearabiotech.com/team/
See also: Cleara Biotech - Cleara is developing therapeutics to eliminate senescent cells.
Details last updated 03-Jun-2019
Peter de Keizer is also referenced in the following:
ARDD 2021 - 8th Aging Research and Drug Discovery Meeting
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
Healthy Ageing (Virtual Conference)
25-May-2022 to 27-May-2022
Virtual conference by Wellcome Connecting Science with Judith Campisi as a keynote speaker
Peter de Keizer News
$2.5M seed financing round closed by Cleara Biotech-targets cellular senescence
Longevity Technology - 03-Oct-2022
Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells
Read more...Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Read more...Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020
General feeling that failures are bound to happen - but that their approaches can succeed
Read more...LEAF report from the Longevity Leaders Conference
Lifespan.io (LEAF) - 06-Feb-2019
Encouraging signs from big companies - more interviews to follow
Read more...Cleara Biotech Joins the Race to Develop Senolytic Therapies
Lifespan.io (LEAF) - 09-Jul-2018
This therapy uses a modified FOXO4 to promote apoptosis in senescent cells
Read more...Hallmark of Aging Reversed by Senescent Cell Removal
Lifespan.io (LEAF) - 25-Mar-2017
Study directly targets one of the mechanisms that senescent cells use to avoid apoptosis, Focuse...
Read more...Science-Backed Therapy Targeting Senescent Cells May Be Future Anti-Aging Serum
Medical Daily - 11-Jan-2017
Growing older results in a build-up of the body’s senescent cells and naturally accumulate with a...
Read more...Anti-aging therapies targeting senescent cells: Facts and fiction
Cell - 29-Dec-2016
Peter de Keizer of the Erasmus University Medical Center discusses strategy of removing senescent...
Read more...Articles written by Peter de Keizer
Anti-aging therapies targeting senescent cells: Facts and fiction
Cell - 29-Dec-2016
Peter de Keizer of the Erasmus University Medical Center discusses strategy of removing senescent...
Read more...